Preoperative serum markers for individual patient prognosis in stage I–III colon cancer

Tumor Biology

Volumn 36, Issue 10, 2015, Pages 7897-7906

  Giessen Jung, Clemens ^a   Nagel, Dorothea ^a   Glas, Maria ^a   Spelsberg, Fritz ^a   Lau Werner, Ulla ^a   Modest, Dominik Paul ^a   Schulz, Christoph ^a   Heinemann, Volker ^a   Di Gioia, Dorit ^a   Stieber, Petra ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

CA 19 9; CEA; Colorectal cancer; Gamma glutamyltransferase; Prognostic factors; Tumor marker

Indexed keywords

25 HYDROXYVITAMIN D; ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; AMYLOID A PROTEIN; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; C REACTIVE PROTEIN; CA 125 ANTIGEN; CA 19-9 ANTIGEN; CA 72-4 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CHORIONIC GONADOTROPIN; CREATININE; CYTOKERATIN 19 FRAGMENT; FERRITIN; GAMMA GLUTAMYLTRANSFERASE; HAPTOGLOBIN; HEMOGLOBIN; INTERLEUKIN 6; INTERLEUKIN 8; LACTATE DEHYDROGENASE; TUMOR MARKER;

ADULT; AGE DISTRIBUTION; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER RISK; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; COLON CANCER; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE FREE SURVIVAL; FEMALE; FERRITIN BLOOD LEVEL; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GONADOTROPIN BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTIVE VALUE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL PREDICTION; SURVIVAL RATE; SURVIVAL TIME; VITAMIN BLOOD LEVEL; BIOASSAY; BLOOD; COLONIC NEOPLASMS; FOLLOW UP; MIDDLE AGED; MORTALITY; PATHOLOGY; PREOPERATIVE CARE; PROGNOSIS; PROSPECTIVE STUDY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL ASSAY; BIOMARKERS, TUMOR; COLONIC NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PREOPERATIVE CARE; PROGNOSIS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84944276774     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3522-z     Document Type: Article

References (28)

1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374–403.
2. Duffy MJ, van Dalen A, Haglund C, Hansson L, Holinski-Feder E, Klapdor R, et al. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer. 2007;43(9):1348–60.
3. Yamashita K, Watanabe M. Clinical significance of tumor markers and an emerging perspective on colorectal cancer. Cancer Sci. 2009;100(2):195–9.
4. Van Cutsem E, Nordlinger B, Cervantes A, Group ObotEGW. Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. Annals of Oncology. 2010;21 suppl 5:v93–7.
5. Spencer SK, Pommier AJ, Morgan SR, Barry ST, Robertson JD, Hoff PM, et al. Prognostic/predictive value of 207 serum factors in colorectal cancer treated with cediranib and/or chemotherapy. Br J Cancer. 2013;109(11):2765–73.
6. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006;24(33):5313–27.
7. Behbehani AI, Al-Sayer H, Farghaly M, Kanawati N, Mathew A, al-Bader A, et al. Prognostic significance of CEA and CA 19-9 in colorectal cancer in Kuwait. Int J Biol Markers. 2000;15(1):51–5.
8. Reiter W, Stieber P, Reuter C, Nagel D, Lau-Werner U, Lamerz R. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer. Anticancer Res. 2000;20(6D):5195–8.
9. Hofmann D, Nagel D, Lau-Werner U, Wichmann Matthias W, Hornung H-M, Stenman Ulf H, et al. Prognosis in non-metastatic colorectal cancer: multivariate evaluation of preoperative levels of six tumor markers in addition to clinical parameters. Lab Med. 2007. p. 76.
10. Louhimo J, Carpelan-Holmstrom M, Alfthan H, Stenman UH, Jarvinen HJ, Haglund C. Serum HCG beta, CA 72-4 and CEA are independent prognostic factors in colorectal cancer. Int J Cancer. 2002;101(6):545–8.
11. Yang XQ, Chen C, Hou JX, Peng CW, Huang CQ, Li Y. Preoperative serum carbohydrate antigen 242 is a useful predictive and prognostic marker in colorectal cancer. Hepatogastroenterology. 2011;58(106):377–82.
12. Webb A, Scott-Mackie P, Cunningham D, Norman A, Andreyev J, O'Brien M, et al. The prognostic value of CEA, beta HCG, AFP, CA125, CA19-9 and C-erb B-2, beta HCG immunohistochemistry in advanced colorectal cancer. Ann Oncol. 1995;6(6):581–7.
13. Holdenrieder S, Stieber P, Liska V, Treska V, Topolcan O, Dreslerova J, et al. Cytokeratin serum biomarkers in patients with colorectal cancer. Anticancer Res. 2012;32(5):1971–6.
14. Proctor MJ, Talwar D, Balmar SM, O'Reilly DS, Foulis AK, Horgan PG, et al. The relationship between the presence and site of cancer, an inflammation-based prognostic score and biochemical parameters. Initial results of the Glasgow Inflammation Outcome Study. Br J Cancer. 2010;103(6):870–6.
15. Tsuboya T, Kuriyama S, Nagai M, Hozawa A, Sugawara Y, Tomata Y, et al. Gamma-glutamyltransferase and cancer incidence: the Ohsaki cohort study. J Epidemiol. 2012;22(2):144–50.
16. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumour MARKer prognostic studies (REMARK). Eur J Cancer. 2005;41(12):1690–6.
17. Giessen C, Nagel D, Glas M, Spelsberg F, Lau-Werner U, Modest DP, et al. Evaluation of preoperative serum markers for individual patient prognosis in stage I–III rectal cancer. Tumour Biol. 2014;35(10):10237–48.
18. Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol. 2012;23(10):2479–516.
19. Park YJ, Park KJ, Park JG, Lee KU, Choe KJ, Kim JP. Prognostic factors in 2230 Korean colorectal cancer patients: analysis of consecutively operated cases. World J Surg. 1999;23(7):721–6.
20. Park YJ, Youk EG, Choi HS, Han SU, Park KJ, Lee KU, et al. Experience of 1446 rectal cancer patients in Korea and analysis of prognostic factors. Int J Color Dis. 1999;14(2):101–6.
21. Mehrkhani F, Nasiri S, Donboli K, Meysamie A, Hedayat A. Prognostic factors in survival of colorectal cancer patients after surgery. Color Dis. 2009;11(2):157–61.
22. Chau I, Allen MJ, Cunningham D, Norman AR, Brown G, Ford HE, et al. The value of routine serum carcino-embryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer. J Clin Oncol. 2004;22(8):1420–9.
23. Pietra N, Sarli L, Costi R, Ouchemi C, Grattarola M, Peracchia A. Role of follow-up in management of local recurrences of colorectal cancer: a prospective, randomized study. Dis Colon Rectum. 1998;41(9):1127–33.
24. Stocchi L, Nelson H, Sargent DJ, O'Connell MJ, Tepper JE, Krook JE, et al. Impact of surgical and pathologic variables in rectal cancer: a United States community and cooperative group report. J Clin Oncol Off J Am Soc Clin Oncol. 2001;19(18):3895–902.
25. Hochwald SN, Harrison LE, Rose DM, Anderson M, Burt ME. gamma-Glutamyl transpeptidase mediation of tumor glutathione utilization in vivo. J Natl Cancer Inst. 1996;88(3-4):193–7.
26. Zhu Y, Yang SR, Wang PP, Savas S, Wish T, Zhao J, et al. Influence of pre-diagnostic cigarette smoking on colorectal cancer survival: overall and by tumour molecular phenotype. Br J Cancer. 2014;110(5):1359–66.
27. Steele SR, Park GE, Johnson EK, Martin MJ, Stojadinovic A, Maykel JA, et al. The impact of age on colorectal cancer incidence, treatment, and outcomes in an equal-access health care system. Dis Colon Rectum. 2014;57(3):303–10.
28. Jafri SH, Mills G. Lifestyle modification in colorectal cancer patients: an integrative oncology approach. Future Oncol. 2013;9(2):207–18.